VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Results of Operations and Financial Condition
Item 2.02
See Item 8.01.
Today, VistaGen Therapeutics Inc. (the “Company”) issued a
press release to provide investors with a corporate update and to
announce the Company’s financial results for its fiscal year
ended March 31, 2017. A copy of the press release is attached
hereto as Exhibit 99.1.
The information furnished herein and therein shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that Section, or incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific
reference in such filing.
(d) Exhibits Index
|
Exhibit No. |
Description |
|
|
99.1 |
Press release issued by VistaGen Therapeutics Inc. dated June 29, 2017. |
Disclaimer.
This Current Report on Form 8-K may contain, among other things,
certain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including,
without limitation, (i) statements with respect to the Company’s
plans, objectives, expectations and intentions; and (ii) other
statements identified by words such as “may”, “could”,
“would”, should”, “believes”, “expects”, “anticipates”,
“estimates”, “intends”, “plans” or similar expressions.
These statements are based upon the current beliefs and
expectations of the Company’s management and are subject to
significant risks and uncertainties.
VistaGen Therapeutics, Inc. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint Exhibit 99.1 VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO,…To view the full exhibit click here About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
